Recently Updated

What changed and when — corrections, retractions, and other meaningful editorial updates, newest first.

Updates

  1. Trial Watch: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    — Status change

    Status changed from "In editorial review" to "Verified".

  2. Trial Watch: A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

    — Status change

    Status changed from "In editorial review" to "Verified".

  3. Trial Watch: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  4. Trial Watch: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  5. Trial Watch: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  6. Trial Watch: A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator’s Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  7. Trial Watch: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  8. Trial Watch: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

    — Status change

    Status changed from "In editorial review" to "Verified".

  9. Trial Watch: Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

    — Status change

    Status changed from "In editorial review" to "Verified".

  10. Trial Watch: Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  11. Trial Watch: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  12. Trial Watch: A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  13. Trial Watch: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  14. Trial Watch: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

    — Status change

    Status changed from "In editorial review" to "Verified".

  15. Trial Watch: Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

    — Status change

    Status changed from "In editorial review" to "Verified".

  16. Trial Watch: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    — Status change

    Status changed from "In editorial review" to "Verified".

  17. Trial Watch: A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

    — Status change

    Status changed from "In editorial review" to "Verified".

  18. Trial Watch: Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

    — Status change

    Status changed from "In editorial review" to "Verified".

  19. Trial Watch: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    — Status change

    Status changed from "In editorial review" to "Verified".

  20. Trial Watch: BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

    — Status change

    Status changed from "In editorial review" to "Verified".

  21. Trial Watch: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

    — Status change

    Status changed from "In editorial review" to "Verified".

  22. Trial Watch: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

    — Status change

    Status changed from "In editorial review" to "Verified".

  23. Trial Watch: A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia

    — Status change

    Status changed from "In editorial review" to "Verified".

  24. Trial Watch: A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  25. Trial Watch: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  26. Trial Watch: Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  27. Trial Watch: Intravesical BCG vs GEMDOCE in NMIBC

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  28. Trial Watch: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  29. Trial Watch: Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

  30. Trial Watch: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    — Status change

    Status changed from "Legacy / Unverified" to "In editorial review".

See the full corrections and retractions policy